Clinical Trial Update: Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment [Phase 1]

View source ↗

Summary

Phase 1 trial of lintuzumab Ac-225, a radiolabeled immunotherapy, for high-risk myelodysplastic syndrome refractory to other treatments has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Lintuzumab Ac-225

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Refractory Myelodysplastic Syndrome | Phase 1 | Status: SUSPENDED